Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3012011 | 1.00 | FFAR3 (0.45) | FFAR3SLC1A3SLC1A2SLC1A1EPHX2 | |
| SCHEMBL602565 | 0.81 | FFAR3 (0.48) | FFAR3 | |
| SCHEMBL602564 | 0.81 | FFAR3 (0.48) | FFAR3 | |
| SCHEMBL600510 | 0.79 | FFAR3 (0.45) | FFAR3EPHX2 | |
| SCHEMBL600536 | 0.79 | FFAR3 (0.45) | FFAR3EPHX2 | |
| SCHEMBL600509 | 0.79 | FFAR3 (0.45) | FFAR3EPHX2 | |
| SCHEMBL12852834 | 0.77 | FFAR3 (0.43) | FFAR3 | |
| SCHEMBL3017120 | 0.77 | FFAR3 (0.43) | FFAR3 | |
| SCHEMBL13213310 | 0.75 | FFAR3 (0.50) | FFAR3SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL600836 | 0.75 | FFAR3 (0.54) | FFAR3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426443-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2013-04-23 | — | — | US | disclosed |
| US-8426443-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2013-04-23 | — | — | US | disclosed |
| US-8426443-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2013-04-23 | — | — | US | disclosed |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2012-12-13 | — | — | US | disclosed |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2012-12-13 | — | — | US | disclosed |
| US-8299257-B2 | Compounds which have activity at M1receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8299257-B2 | Compounds which have activity at M1receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8278328-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-8278328-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-20100210687-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210687-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | Glaxo Group Limited a corporation | 2010-08-12 | — | — | US | disclosed |
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | Glaxo Group Limited a corporation | 2010-08-12 | — | — | US | disclosed |
| EP-2194983-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | Glaxo Group Limited (GB) | 2010-06-16 | — | — | EP | disclosed |
| EP-2194982-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | Glaxo Group Limited (GB) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009037294-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037296-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037296-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037294-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210687-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | FFAR3 303/4885SLC1A3 481/4885SLC1A2 170/4885 |
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | FFAR3 303/4885SLC1A3 481/4885SLC1A2 170/4885 |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | CHRM1, CHRM2, CHRM5 | FFAR3 303/4885SLC1A3 481/4885SLC1A2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.